Oxygen Biotherapeutics, Inc. Company Profile
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
News Articles
Valor, Oxygen Biotherapeutics enter License and Supply Agreement for Dermacyte
Oxygen Biotherapeutics, Inc., announced today that it has entered into a License and Supply Agreement with the Cosmetics Division of Valor SA of Lausanne, Switzerland, for Dermacyte, a perfluorocarbon...
Oxygen Biotherapeutics relocating R&D function to North Carolina
Oxygen Biotherapeutics, a Morrisville, N.C.-based developer of medical and cosmetic products that efficiently deliver oxygen to tissues in the body, is searching for laboratory space in the Research T...
Oxygen Biotherapeutics first quarter net loss increases to $3.6 million
Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing intravenous and topical oxygen-carrier products, today announced results for the fiscal year (FY) 2013 first...
Oxygen Biotherapeutics Announces Second Quarter FY2013 Financial Results Conference Call and Webcast
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company plans to report second quarter fiscal year 2013 financial results on Form 10-Q on Friday, December 14,...
Oxygen Biotherapeutics Announces First Quarter FY2013 Financial Results Conference Call and Webcast
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company plans to report first quarter fiscal year 2013 financial results on Form 10-Q on Wednesday, September...
Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company plans to report third quarter fiscal year 2013 financial results on Form 10-Q on Monday, March 18, 201...
Oxygen Biotherapeutics proposes private placement of units
Oxygen Biotherapeutics Study Reveals Dermacyte(R) Concentrate's Potential to Relieve ...
Drugs and Medications
Oxygen [Norton Sound Health Corporation]
Oxygen, Compressed
Liquid Oxygen
Oxygen [Reliance Oxygen & Equipment]
Oxygen [Cranston Welding Supply Company]
Oxygen [Two MP Investments, Inc. dba Respicare]
Oxygen
PubMed Articles
Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-based molecules, have emerged as an important class of pharmaceuticals. Aggregation and immunogenicity are among th...
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration.
The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion...
Subcutaneous administration of biotherapeutics: Current experience in animal models.
In recent years, many peptide- and protein-based biotherapeutics have been approved for subcutaneous (SC) delivery. The mechanisms and factors affecting the uptake and distribution of such large molec...
Protein Particulate Detection Issues in Biotherapeutics Development-Current Status.
Formation of aggregates and particulates in biopharmaceutical formulation continues to be one of the major quality concerns in biotherapeutics development. The presence of large quantities of aggregat...
An immune response to a biotherapeutic can be induced when the therapeutic is processed and presented by antigen presenting cell to T helper cells. This study evaluates the performance of an in vitro...
Clinical Trials
Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers
Patients with lung disease experiencing difficulty breathing can be treated with oxygen therapy. This involves the delivery of "extra" oxygen by a face-mask or through small tubes placed...
Oxygen Portable Concentrator During Exercises in Patients With COPD
The purpose of this study is to compare differences in oxygen delivery between portable oxygen concentrators (POCs) and liquid oxygen (LOs) portable units, pose a question if POCs are equa...
Pre-flight Titration of Supplemental Oxygen
The purpose of this study is to evaluate if supplemental oxygen during air travel can be reliably titrated using a Hypoxia-altitude simulation test (HAST). Also, the effect of oxygen suppl...
To compare the efficacy of long-term use of nocturnal oxygen therapy (12 hours) with that of continuous, low-flow oxygen therapy (24 hours) in patients with chronic hypoxic lung disease.
Study Question: In infants who are born at gestational ages of 23 0/7 to 27 6/7 weeks, does lowering the concentration of supplemental oxygen to target an arterial oxygen saturation by pul...
Companies
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a pe...
SeQual Technologies, founded in 1991, develops, manufactures and markets products for medical, military, industrial and commercial applications that utilize the Company's proprietary pressure swing ad...
We are the innovators and manufacturers of cost efficient, user friendly stationary and ambulatory oxygen systems designed for use by patients diagnosed with COPD and other respiratory disorders. As...
Napro Biotherapeutics Incorporated
NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent...
EpiFLOSD consists of a small, silent, disposable, oxygen concentrator and a 43" long sterile cannula (tube). It is used with any fully occlusive sterile wound dressing to continuously blanket the woun...
More Information about "Oxygen Biotherapeutics, Inc." on BioPortfolio
We have published hundreds of Oxygen Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Oxygen Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Oxygen Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxygen Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Oxygen Biotherapeutics, Inc. Drugs and Medications on this site too.
